Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial Condition

Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition.

On March9, 2017, Egalet Corporation issued a press release
announcing its financial results for its fourth quarter and year
ended December31, 2016. A copy of that press release and the
attached financial schedules are attached as Exhibit99.1 to this
report and incorporated herein by reference.

The information in this report (including Exhibit99.1) is being
furnished to Item 2.02 and shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed to be incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange
Act.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNumber

Description

99.1

Press Release, dated March9, 2017, announcing financial
results for the fourth quarter and year ended December31,
2016.


About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Egalet Corporation (NASDAQ:EGLT) Recent Trading Information

Egalet Corporation (NASDAQ:EGLT) closed its last trading session 00.00 at 4.62 with 171,110 shares trading hands.

An ad to help with our costs